Press ESC to close

Peptide Lab App Log in Articles News Guide Products
More Peptide Tracker Calculator Best Calculators Peptide Statistics Contact Newsletter
Français English Deutsch Español Português العربية Italiano Polski 한국어 日本語 中文 Русский Nederlands Čeština Svenska Türkçe
TB
500

TB-500

Thymosin Beta-4 Fragment

889.0 g/mol Molecular Weight
C38H68N10O14 Formula
Active research Status
Ac-LKKTETQ (thymosin beta-4 residues 17-23)
Updated on November 7, 2026
TB-500 Photo: Andrea Piacquadio
BPC-157 & TB-500: The Recovery Stack ExplainedEnglish, subtitles FR · ES · DE · IT · PT

Overview

TB-500 is a synthetic peptide derived from thymosin beta-4 (TB4), a 43-amino acid protein naturally present in nearly all nucleated cells of the body. Thymosin beta-4 was initially isolated from the thymus in the 1960s, but subsequent research revealed its ubiquitous expression in human tissues, with particularly high concentrations in blood platelets, leukocytes, and migrating cells.

TB-500 contains the active sequence of thymosin beta-4, notably the central LKKTETQ domain, identified as the primary motif responsible for the protein's biological activity on cell migration and tissue repair. This fragment retains the key properties of the parent molecule while offering better experimental manageability and a reduced molecular mass.

Thymosin beta-4 is the main sequestering peptide of G-actin (monomeric actin) in eukaryotic cells. This fundamental function in actin cytoskeleton regulation gives it a central role in cell motility, morphogenesis, and tissue repair processes. Research on TB-500 falls within the broader field of regenerative medicine and wound healing biology. TB-500 is a key component of blends such as Klow Peptide and Glow Peptide.

In Europe, TB-500 is also available as a pre-filled pen. Our guide to pre-filled peptide pens explains how this format differs from a vial (price per mg, stability).

🧮 TB-500 Reconstitution Calculator

Mechanism of Action

The primary mechanism of action of TB-500 is based on actin cytoskeleton regulation. Thymosin beta-4 binds to monomeric G-actin with a 1:1 stoichiometry, forming a complex that prevents spontaneous polymerization of actin into filaments (F-actin). By regulating the available G-actin pool, TB-500 controls cytoskeletal dynamics, a process essential for cell migration, lamellipodia formation, and cytokinesis.

Beyond actin sequestration, TB-500 activates several signaling pathways involved in tissue repair. It stimulates the Akt/mTOR pathway, promoting cell survival and apoptosis inhibition. The peptide also induces the expression of vascular endothelial growth factor (VEGF) and angiopoietin-1, promoting angiogenesis in injured tissues. Studies have shown that TB-500 upregulates laminin-5 and beta-3 integrin, proteins involved in cell adhesion and migration.

TB-500 also exerts significant anti-inflammatory effects. It modulates the NF-kB pathway, reducing the production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and attenuating inflammatory cell recruitment to the injury site. This dual action, pro-regenerative and anti-inflammatory, creates a microenvironment favorable to wound healing, limiting fibrotic scar tissue formation in favor of more complete tissue regeneration.

Studied Benefits

Post-infarction cardiac repair

Preclinical studies in murine models of myocardial infarction have shown that thymosin beta-4 reduces the size of the infarcted area, improves left ventricular contractile function, and stimulates neovascularization of injured cardiac tissue. These effects are attributed to the activation of cardiac progenitor cells and the anti-apoptotic effect of the peptide.

Accelerated skin wound healing

Thymosin beta-4 accelerates skin wound healing in animal models by stimulating keratinocyte and endothelial cell migration, increasing angiogenesis, and promoting organized collagen deposition. Studies on chronic wound models (diabetic) show a significant improvement in closure time.

Neuroprotection and neuronal regeneration

Research on models of traumatic brain injury and stroke has shown that thymosin beta-4 reduces neuronal inflammation, promotes oligodendrocyte survival, and stimulates remyelination. The peptide improves functional neurological scores in animal models of central nervous system injuries.

Corneal injury repair

One of the most clinically advanced applications of thymosin beta-4 concerns corneal wound healing. Phase II clinical trials (RGN-259) have evaluated the efficacy of topical ophthalmic thymosin beta-4 in the treatment of dry eye disease and neurotrophic corneal lesions, with encouraging results.

Research Status

Research on thymosin beta-4 and TB-500 covers a broad disciplinary spectrum, from fundamental cell biology to clinical trials. The scientific literature comprises over 300 peer-reviewed publications, with a notable acceleration of research since the pioneering work of Sosne and Kleinman on regenerative effects in the 2000s.

The most robust preclinical studies concern regenerative cardiology and skin wound healing. The work of Bock-Marquette and collaborators (2004) demonstrated the cardioprotective effect of thymosin beta-4 in a murine model of myocardial ischemia, a finding confirmed by several independent teams. In ophthalmology, the clinical development of RGN-259 (topical thymosin beta-4 formulation) represents the most advanced therapeutic application, with Phase II/III trials for dry eye disease.

Current limitations include the complexity of the mechanisms of action, which makes it difficult to identify predictive biomarkers of response, the lack of detailed pharmacokinetic data for synthetic TB-500, and the difficulty of translating effective doses from animal models to humans. TB-500 is also listed on the World Anti-Doping Agency (WADA) prohibited substances list, due to its potential for enhancing tissue recovery.

Safety and Side Effects

The safety profile of thymosin beta-4 is generally favorable in published preclinical studies. Acute and chronic toxicity studies in rodents and dogs have not revealed significant toxicity at therapeutic doses. In ophthalmic clinical trials (RGN-259), the topical thymosin beta-4 formulation was well tolerated, with no serious adverse effects attributable to the treatment.

A theoretical concern involves the potential role of thymosin beta-4 in tumor progression. Indeed, elevated levels of thymosin beta-4 have been observed in certain types of tumors, and the peptide could theoretically promote tumor angiogenesis and metastasis by increasing cell motility. However, available studies do not demonstrate that exogenous administration of thymosin beta-4 induces or accelerates carcinogenesis, and the peptide has even shown anti-tumor effects in certain models.

For TB-500 specifically, human safety data are limited, as the majority of clinical trials use complete thymosin beta-4 rather than the synthetic fragment. Anecdotally reported side effects include transient headaches, mild lethargy, and injection site discomfort. The use of TB-500 remains within the scope of experimental research, and its status as a WADA-prohibited substance underscores the need for strict oversight.

What the evidence does not show

  • No controlled human trial of the fragment for injuries. FDA's 2026 review did not identify any clinical study of TB-500 in humans, and none of the 43 references submitted with the nomination studied TB-500 in people. FDA also found no in vivo study of TB-500 for wound healing; in the one cell study it identified, TB-500 did not induce closure of scratch wounds in fibroblast cultures. A 2026 orthopaedic review found that direct musculoskeletal evidence for thymosin beta-4 is limited to cell and rodent studies (Tham et al., 2026).
  • The human trials concern full-length thymosin beta-4. RegeneRx and ReGenTree tested thymosin beta-4 eye drops (RGN-259) in dry eye and neurotrophic keratopathy, and earlier in skin ulcers. Beijing Northland Biotech is testing recombinant thymosin beta-4 (NL005) given intravenously after myocardial infarction. These results cannot be transferred to a 7-amino-acid fragment, because the two have not been shown to be biologically equivalent.
  • Long-term safety is unknown. FDA found no genotoxicity, reproductive toxicity or carcinogenicity studies of TB-500. Animal data show that the fragment is broken down into smaller peptides, and the HHS appendix notes that it is rapidly truncated in human serum. The safety record of full-length thymosin beta-4 does not settle the safety of the fragment.
  • The content of a vial is uncertain. FDA reports that several salts and derivatives, including different active moieties, are sold under the name TB-500; in the nomination it reviewed, the molecular formula matched neither the free base nor the acetate. A French horse-racing laboratory found that TB500 and TB1000 products bought online did not consistently match their description (Delcourt et al., 2023).

Human research in 2025-2026

As of November 2026, no peer-reviewed study of TB-500 (Ac-LKKTETQ) in humans has been published, and FDA's July 2026 review did not identify one. Human research continues on full-length thymosin beta-4:

  • Myocardial infarction (recombinant thymosin beta-4, NL005). A phase 1 study in 84 healthy volunteers reported only mild to moderate adverse events and no serious adverse events (Wang et al., 2021). Beijing Northland Biotech then completed a phase 2b trial in 90 patients treated by PCI (NCT05984134, completed May 2023, no results posted). A phase 2c trial in 189 patients with STEMI (NCT07586865) is registered with infarct size on cardiac MRI at 90 days as its main endpoint; it was listed as not yet recruiting.
  • Eye (RGN-259 eye drops). ReGenTree's phase 3 SEER-2 trial in neurotrophic keratopathy (NCT05555589, 70 participants) was completed in July 2026. No results had been posted on ClinicalTrials.gov at the time of writing.
  • Reviews. Narrative reviews published in 2026 in Sports Medicine and in the Journal of the American Academy of Orthopaedic Surgeons conclude that rigorous human safety data are scarce and that TB-500 is frequently conflated with full-length thymosin beta-4 without any proven equivalence (Mendias and Awan, 2026; Tham et al., 2026).

Test your knowledge

Quick quiz · 6 questions

🏆

Where to buy this peptide?

We analyzed the best suppliers to help you find a quality, lab-tested product.

See our selection →

TB-500: all our articles

Frequently Asked Questions

What is the difference between TB-500 and thymosin beta-4?
Thymosin beta-4 (TB4) is the complete natural protein of 43 amino acids. TB-500 is a synthetic peptide that contains the active region of TB4, including the LKKTETQ motif responsible for the majority of biological activities. TB-500 is more commonly used in preclinical research due to its lower production cost and greater ease of handling.
Is TB-500 banned in sports?
Yes, TB-500 is listed on the World Anti-Doping Agency (WADA) prohibited substances and methods list in the S2 category (peptides, growth factors, and related substances). Its use is prohibited both in-competition and out-of-competition for athletes subject to anti-doping rules. This classification reflects the peptide's potential to enhance tissue recovery.
What are the most advanced research areas for TB-500?
The most advanced areas are ophthalmology (treatment of dry eye disease and corneal injuries with RGN-259 in Phase II/III), regenerative cardiology (post-infarction repair), dermatology (chronic wound healing), and neurology (recovery after traumatic brain injury and stroke).
Can TB-500 promote cancer?
This is a legitimate question that is the subject of ongoing research. Elevated levels of thymosin beta-4 have been associated with certain cancers, but this correlation does not imply causation. Current studies do not demonstrate that exogenous administration of TB4 or TB-500 causes or accelerates tumor growth. Some work even suggests anti-tumor properties in specific models. Further research is needed to clarify this question.
What is the exact chemical identity of TB-500?
In FDA's 2026 review and in PubChem (CID 62707662), TB-500 is N-acetyl-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), residues 17 to 23 of thymosin beta-4, with the formula C38H68N10O14 and a molecular weight of about 889 g/mol. The acetate salt named in the HHS policy weighs 949.1 g/mol. Because the name is not standardized, some products sold as TB-500 are described as full-length thymosin beta-4 (C212H350N56O78S, about 4,963 g/mol). Only a certificate of analysis that states the sequence and the measured mass shows which molecule a product contains.
What does the HHS policy of October 2026 change for TB-500?
TB-500 is still not approved. Since 28 October 2026, HHS does not intend to take enforcement action against State-licensed 503A pharmacies, Federal facilities or licensed physicians that compound TB-500 acetate for an individual patient's prescription, under conditions (FDA-registered active ingredient with a certificate of analysis, single ingredient, subcutaneous or intramuscular forms). The policy is temporary, does not apply to research-use-only products or to full-length thymosin beta-4, and is not a listing on the 503A bulks list.
Has TB-500 been tested in human clinical trials?
No controlled trial of the fragment has been published. FDA's 2026 review did not identify any clinical study of TB-500 in humans. The human trials that are often cited (RGN-259 eye drops, recombinant thymosin beta-4 after a heart attack) used full-length thymosin beta-4, a different and much larger molecule.

Scientific Sources

  1. Goldstein AL, Hannappel E, Sosne G, et al. (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 12(1), 37-51. (PubMed · DOI)
  2. Bock-Marquette I, Saxena A, White MD, et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466-472. (PubMed · DOI)
  3. Sosne G, Qiu P, Goldstein AL, et al. (2010). Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal, 24(7), 2144-2151. (PubMed · DOI)
  4. Philp D, Badamchian M, Scheremeta B, et al. (2003). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration, 11(1), 19-24. (PubMed · DOI)
  5. Crockford D, Turjman N, Allan C, et al. (2010). Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences, 1194(1), 179-189. (PubMed)
  6. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P (2012). Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis, 4(9), 733-738. (PubMed · DOI)
  7. Delcourt V, Garcia P, Chabot B, et al. (2023). TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Testing and Analysis, 15(4), 458-464. (PubMed · DOI)
  8. Wang X, Liu L, Qi L, et al. (2021). A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine, 25(17), 8222-8228. (PubMed · DOI)
  9. Mendias CL, Awan TM (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine, 56(8), 1921-1935. (PubMed · DOI)
  10. Tham A, Hodgkins CW, Kennedy JG (2026). Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. Journal of the American Academy of Orthopaedic Surgeons (online ahead of print). (PubMed · DOI)
  11. National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 62707662, TB-500 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH). PubChem. (pubchem.ncbi.nlm.nih.gov)
  12. U.S. Food and Drug Administration (2026). FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: TB-500-related bulk drug substances (TB-500 free base and TB-500 acetate). FDA. (fda.gov)
  13. U.S. Department of Health and Human Services (2026). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice 2026-22192, docket HHS-OASH-2026-0496). Federal Register, 30 October 2026. (federalregister.gov)
  14. World Anti-Doping Agency (2026). World Anti-Doping Code International Standard: Prohibited List 2026 (S2, growth factors: thymosin-β4 and its derivatives e.g. TB-500). WADA. (wada-ama.org)
  15. Australian Government, Federal Register of Legislation (2026). Therapeutic Goods (Poisons Standard, October 2026) Instrument 2026 (F2026L01327): TB-500 and thymosin beta 4, Schedule 4 and Appendix D clause 5. legislation.gov.au. (legislation.gov.au)
  16. Beijing Northland Biotech. Co., Ltd. (2026). Phase IIc study of recombinant human thymosin beta 4 injection (NL005) in patients with acute myocardial infarction (NCT07586865). ClinicalTrials.gov. (clinicaltrials.gov)
  17. Beijing Northland Biotech. Co., Ltd. (2023). Efficacy and safety of recombinant human thymosin β4 (NL005) for injection in patients with acute myocardial infarction: a phase IIb clinical study (NCT05984134). ClinicalTrials.gov. (clinicaltrials.gov)
  18. ReGenTree, LLC (2026). SEER-2: phase 3 study of 0.1% RGN-259 ophthalmic solution for neurotrophic keratopathy (NCT05555589). ClinicalTrials.gov. (clinicaltrials.gov)

This content is for informational and educational purposes only. It does not constitute medical advice. Consult a healthcare professional before making any decisions. Read our full medical disclaimer

TB-500
TB-500
Muscle Recovery →